Sign In
Buy RHHBY
$51.57
+2.51 (+5.12%)
At Close: Jun 04, 2026
PLEASANTON, Calif., May 18, 2021 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its cobas® SARS-CoV-2 Test for use on the widely available, high-throughput cobas® 6800/8800
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new data from clinical trials of 19 approved and investigational
The 3 Safest Dividend Blue-Chips To Help You Sleep Well At Night
11:09pm, Sunday, 09'th May 2021
The 3 Safest Dividend Blue-Chips To Help You Sleep Well At Night
Basel, 5 May 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq® (atezolizumab) as a first-line (initial) treatment for adults with metast
ARK Genomic Revolution ETF: Value Realization Will Take Time
04:46am, Monday, 03'rd May 2021
ARK Genomic Revolution ETF: Value Realization Will Take Time
The Hanover Insurance Group, Inc. (THG) CEO Jack Roche on Q1 2021 Results - Earnings Call Transcript
06:48pm, Friday, 30'th Apr 2021
The Hanover Insurance Group, Inc. (THG) CEO Jack Roche on Q1 2021 Results - Earnings Call Transcript
Oncologic Drugs Adcomm Backs Merck's Keytruda, Roche's Tecentriq Accelerated Approvals In Bladder Cancer
11:47am, Thursday, 29'th Apr 2021
The FDA's Oncologic Drugs Advisory Committee voted 5-3 in favor of keeping Merck & Co's (NYSE: MRK) Keytruda (pembrolizumab) accelerated approval alive as a first-line bladder cancer treatment, eve
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory
Roche launches new ways to use their cardiovascular tests empowering clinicians to improve diagnosis and treatment of millions of people
01:00am, Wednesday, 28'th Apr 2021
Basel, 28 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced a series of five new intended uses for two key cardiac biomarkers using the Elecsys® technology: high sensitive cardiac troponin T
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory
Basel, 28 April 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 7 to 2 in favour of maintaini
FDA to discuss whether immuno-oncology drugs with 'accelerated' approval should remain on the market
08:13am, Monday, 26'th Apr 2021
The Food and Drug Administration advisory committee plans to hold a three-day meeting this week to evaluate a type of quicker approval used primarily for immuno-oncology drugs that are thought to help
Disruptor Alert: These 2 Companies Are Changing Cancer Care
06:12am, Saturday, 24'th Apr 2021
Their liquid biopsies are giving doctors new and better tools to spot, track, and treat cancers.
Wide-Moat Stocks On Sale - The May 2021 Heat Map
01:31pm, Friday, 23'rd Apr 2021
Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). e are only interested in those targets that are attractively valued in historical comparison.
Basel, 23 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval
